Merck announced that the company has completed the acquisition of assets of Takeda Biomedical CN201. CN201 is a novel investigational clinical-stage bispecific antibody for treating B cell-related diseases.
默沙东已完成对同润生物医药B细胞耗竭疗法在研药物CN201的收购
Merck has completed the acquisition of Tongrun Biomedical's cell depletion therapy investigational drug CN201.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated